Phase I Study of CPI-300 in Patients With Advanced Tumors

Summary

This is a prospective, open-label, single arm, non-randomized study of CPI-300 in patients with advanced tumors. CPI-300 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD).

Timeline

Start

2021-06-15

Primary completion

2023-12-15

Completion

2023-12-15

Drugs

Indications